A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice.
about
The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to manModelling clinical systemic lupus erythematosus: similarities, differences and success storiesTargeting cell surface TLR7 for therapeutic intervention in autoimmune diseases.The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis?The emerging role of the inflammasome in kidney diseasesImmunomodulatory spherical nucleic acids.Targeting the inflammasome in rheumatic diseases.Scavenging nucleic acid debris to combat autoimmunity and infectious disease.Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity.The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets.Nucleic acid-sensing TLRs and autoimmunity: novel insights from structural and cell biology.Identification of an optimized 2'-O-methylated trinucleotide RNA motif inhibiting Toll-like receptors 7 and 8.The protective effect of the anti-Toll-like receptor 9 antibody against acute cytokine storm caused by immunostimulatory DNA.TLR7 Engagement on Dendritic Cells Enhances Autoreactive Th17 Responses via Activation of ERK.Modulation of toll-like receptor signaling by antimicrobial peptides.TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE.
P2860
Q26825196-3D221AC3-E8A1-4B50-9B18-EE901C77E4A5Q28074217-A62A0CFE-8CEC-4A5E-9B31-823AAB062AD9Q33420162-D8C1E1EF-7473-4CB4-AF86-7A0A28A55198Q34127758-D7285165-BA59-4731-A24E-FD18A6B68C97Q34307043-13C190ED-B47B-428D-B539-0F8F16F9C40BQ35279697-5F9AF387-9FD9-4C9A-811A-801592002EECQ35804717-8C9067E6-E204-4520-9E01-0B77660C3A53Q37258447-2E9C1202-393C-4517-9666-1A531D9FF007Q37598017-1B5DEE42-559F-4FA5-AF16-52CEF6483142Q38235741-4EDB7B93-CD58-43BB-B5F5-0AAA4663FB9BQ38673412-16B10582-3E01-4615-9A1A-257663AA8F8BQ38675405-0985689A-BBA9-4EA2-A85D-0343B453D00DQ41877443-DF62ED0A-3C2C-463B-B19E-2853C8692977Q45972858-04DE51D4-6C8B-487D-8186-74A424E342EEQ50060087-0FE9762E-EA3F-40FB-99F2-3C9B943EC623Q52659628-86449250-E624-4E96-8204-8BB47C2D1D23
P2860
A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A novel antagonist of Toll-lik ...... ed parameters in NZBW/F1 mice.
@en
A novel antagonist of Toll-lik ...... ed parameters in NZBW/F1 mice.
@nl
type
label
A novel antagonist of Toll-lik ...... ed parameters in NZBW/F1 mice.
@en
A novel antagonist of Toll-lik ...... ed parameters in NZBW/F1 mice.
@nl
prefLabel
A novel antagonist of Toll-lik ...... ed parameters in NZBW/F1 mice.
@en
A novel antagonist of Toll-lik ...... ed parameters in NZBW/F1 mice.
@nl
P2093
P2860
P1433
P1476
A novel antagonist of Toll-lik ...... ed parameters in NZBW/F1 mice.
@en
P2093
Daqing Wang
Ekambar R Kandimalla
Fu-Gang Zhu
Jimmy X Tang
Lakshmi Bhagat
Nicola La Monica
Sudhir Agrawal
Weiwen Jiang
P2860
P304
P356
10.3109/08916934.2013.798651
P577
2013-06-12T00:00:00Z